Skip to main content
HR 1530 107th Congress House Commerce Administrative procedure Antitrust law Civil actions and liability Drug approvals Drug industry Federal Trade Commission Fines (Penalties) Generic drugs Government Operations and Politics Government paperwork Health Independent regulatory commissions Injunctions Law Marketing Pharmaceutical research Research and development Restrictive trade practices Science, Technology, Communications

Prescription Drug Competition Act of 2001

Introduced: April 4, 2001 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 107th Congress ended
It never became law before the 107th Congress (2001–2002) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 11, 2001
Sponsor introductory remarks on measure. (CR S10642-10643)
Apr 25, 2001
Referred to the Subcommittee on Health.
Apr 4, 2001
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 4, 2001
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service
Prescription Drug Competition Act of 2001 - Requires brand name drug companies and generic drug applicants to file with the Federal Trade Commission and the Secretary of Health and Human Services specified information regarding any agreement regarding the sale or manufacture of a generic drug which the Secretary has determined is the therapeutic equivalent of the brand name drug or for which the applicant seeks a determination of therapeutic equivalence, if such agreement could have the effect of limiting the research, development, manufacture, marketing, or selling of a generic drug product.
What's happening now October 11, 2001

Sponsor introductory remarks on measure. (CR S10642-10643)

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 3
 Cosponsors 1
All 1 Democratic 1
D
DeLauro, Rosa L.
Connecticut · Jan 29, 2002
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 1530: Prescription Drug Competition Act of 2001. 107th Congress. Open America. https://openamerica.io/bill/107-HR-1530/
MLA
"H.R. 1530: Prescription Drug Competition Act of 2001." 107th Congress, 2026, Open America, https://openamerica.io/bill/107-HR-1530/.
Bluebook (legal)
H.R. 1530, 107th Cong. (2026), https://openamerica.io/bill/107-HR-1530/.
Markdown link
[H.R. 1530: Prescription Drug Competition Act of 2001](https://openamerica.io/bill/107-HR-1530/)
Report a problem